Brain Health

The Sleep Evidence: Five Sleep Problems and What Each Means for Dementia.

Five sleep problems, what each one is linked to, and which ones are worth acting on. This is the summary post for the series, written to stand on its own.

Atif Hashmi

— 21 min read
Share

This is the last post in the sleep series. It should work whether or not you read the earlier four, which covered how much sleep, what sleep does for the brain, what happens when sleep itself becomes the disorder, and whether treating those disorders helps. This one pulls it together and adds the piece I never got to, which is circadian timing.

Sleep duration and regularity: about seven hours, and the same hours each night

The seven-hour curve

Sleep duration tracks dementia risk in a U-shape. Research across more than 1.3 million people finds higher risk at both ends, with the low point around seven hours a night.

Under seven hours carries roughly 18 to 27% higher risk. Over eight hours carries 28 to 66% higher risk.

The two ends of that curve are probably not the same thing. Short sleep has a plausible mechanism, described below. Long sleep more likely reflects something else going on: early brain changes, depression, inflammation, or metabolic disease. Sleeping more does not appear to damage the brain, but it often signals that something else already is.

Whether short sleep contributes to dementia or is an early sign of it is still argued. One meta-analysis found the short-sleep association held in studies with under 10 years of follow-up but not beyond, which would suggest an early sign rather than a cause. The Whitehall II study cuts the other way. It followed people for 25 years and found that sleeping six hours or less at ages 50 and 60 predicted later dementia. Twenty-five years is long enough that reverse causation gets harder to argue.

Why sleep matters: the brain has a cleaning system

The explanation comes down to something discovered in the last decade, the glymphatic system. It is the brain’s waste-disposal network, a system of channels around the blood vessels that flushes out toxic proteins. Those include amyloid-beta and tau, the two that build up in Alzheimer’s. In rodent studies, this cleaning system is far more active during sleep than during wakefulness. The fluid-filled space between brain cells expands by about 60% during sleep, and amyloid clears roughly twice as fast. The system runs hardest during deep, slow-wave sleep. The proposed explanation is that short sleep leaves less time for that clearance to happen. That sequence has been shown in animals, though it has not been measured directly in people.

Which stage you lose matters more than the total

Total hours are not the whole story. The clearest evidence comes from the Framingham Heart Study. It is the only work that measured sleep stages in the same people twice, five years apart, then followed them for 17 years. Each 1% yearly drop in slow-wave sleep, the deep stage when clearance runs hardest, was associated with a 27% higher dementia risk. No other sleep stage predicted dementia in that analysis. People who went on to develop dementia had lost slow-wave sleep at roughly twice the rate of those who stayed healthy, and the loss was faster in APOE ε4 carriers. An earlier analysis from the same cohort found that lower REM sleep also tracked with higher dementia risk. Both are observational, and neither shows that protecting a sleep stage prevents anything, but together they connect the clearance mechanism to a human outcome more directly than duration alone does.

Regularity may matter as much as duration

Going to bed and waking at consistent times matters as much as how long you sleep, and possibly more. The most irregular sleepers face up to 53% higher dementia risk compared to those with moderate regularity, and this association holds even after accounting for how long people sleep. Irregular sleepers also have measurably smaller hippocampi, the brain region most critical for memory and most vulnerable to Alzheimer’s disease. Regular timing appears to partly make up for imperfect duration. regular sleepers who got too little or too much sleep still had 26% lower dementia risk than irregular sleepers with the same total sleep time.

In practice that points to roughly 7 hours a night, and, just as importantly, going to bed and waking at about the same time every day, weekends included.

Obstructive sleep apnea: the most treatable problem on this list

What it is, and how common

In obstructive sleep apnea, the airway repeatedly collapses during sleep. Breathing stops briefly, sometimes hundreds of times a night. Each episode drops blood oxygen, triggers a brief arousal to reopen the airway, and the cycle repeats. Most people have no idea it is happening. Bed partners notice the snoring, gasping, or choking.

It is also common enough that most cases go unrecognized. Counting breathing pauses on a sleep study, roughly one-third of all adults and over 60% of older adults cross the diagnostic threshold. Many have no symptoms and would never be diagnosed clinically, and most cases never are. Meta-analyses consistently show that OSA is associated with 26 to 43% higher dementia risk, with the strongest associations for Alzheimer’s disease (28 to 45% higher risk). The same analyses found no significant association with vascular dementia.

How it damages the brain

The main route is intermittent hypoxia, the repeated drop and recovery of oxygen that comes with each breathing pause. These cycles generate oxidative stress, similar to rust forming on metal. They also activate inflammatory pathways in the brain and impair the glymphatic waste-clearance system discussed above. In laboratory work, they enhance the seeding and spread of pathological tau protein, one of the two hallmark proteins of Alzheimer’s disease. In a small imaging study, it was the severity of oxygen drops during REM sleep specifically, rather than the fragmentation of sleep, that tracked with white matter damage, thinning in memory-related regions, and worse memory.

OSA is also associated with worse Alzheimer’s biomarkers across the board. People with untreated OSA show lower levels of amyloid-beta in spinal fluid (indicating it is being deposited in the brain rather than cleared), higher amyloid on brain PET scans, higher levels of phosphorylated tau, and impaired glymphatic function.

Does treating it help?

The treatment evidence points in two directions at once. The largest observational study matched 193,600 people with OSA against 536,701 without. Patients using CPAP, the mask worn during sleep that holds the airway open, had a dementia risk similar to people who never had OSA. That estimate was imprecise, with a hazard ratio of 0.99 and an interval running from 0.74 to 1.32, and the authors call for further evaluation. Randomized trials of CPAP have not consistently shown cognitive benefit, so this remains an observational finding rather than proof that treatment prevents dementia. That same study also found a pattern opposite to the meta-analyses above, with the association strongest for vascular dementia and no significant association with Alzheimer’s disease, so which subtype OSA most affects is unsettled. In insurance claims data, where adherence was inferred from equipment billing codes rather than measured, CPAP adherence was associated with 35% lower odds of developing Alzheimer’s disease. Studies have also reported that CPAP can partially reverse white matter damage and improve cognitive function in some domains after 6 months of treatment. Pooling randomized trials found only a small effect, on attention.

OSA is among the more treatable of the conditions in this domain. If someone snores loudly, feels excessively tired during the day, or has been told they stop breathing during sleep, testing and treatment are worth discussing with a clinician.

Insomnia: common, and the risk sits in a specific subtype

How common, and what drives it

Insomnia means difficulty falling asleep, staying asleep, or waking too early. It is the most common sleep disorder. Symptoms affect 30 to 40% of adults and up to 75% of older adults. Apnea is a mechanical problem with the airway. Insomnia is a different kind of problem, generally understood as hyperarousal, where the brain’s stress-response system stays switched on and will not fully disengage.

Meta-analyses show that insomnia is associated with 13 to 53% higher dementia risk, with the strongest associations for Alzheimer’s disease (49% increased risk) and vascular dementia (59% increased risk).

The route to the brain is different as well. Apnea works through oxygen deprivation, while insomnia may work partly through stress hormones. People with insomnia have persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis, the body’s central stress-response system, resulting in elevated cortisol levels around the clock, not just at night. Chronically elevated cortisol may promote the production of amyloid-beta, drive tau hyperphosphorylation, which makes tau proteins more likely to form the toxic tangles seen in Alzheimer’s, shrink the hippocampus, and activate neuroinflammation. The picture, if it holds, is a brain kept under constant stress-hormone exposure, which could speed up the same processes involved in Alzheimer’s.

Not all insomnia carries the same risk

The most concerning form is the “insomnia with short sleep” phenotype, people who not only have difficulty sleeping but who objectively sleep fewer hours when measured in a sleep lab. These individuals carry greater amyloid burden on PET and more white matter damage than people with insomnia who sleep a normal number of hours. In the same cohort, chronic insomnia overall was associated with faster cognitive decline, running at roughly 60% of the annual rate seen in people carrying the APOE ε4 gene, the strongest common genetic risk factor for Alzheimer’s disease. Insomnia may also contribute to dementia through a dual pathway, both the Alzheimer’s pathway (amyloid and tau) and the cerebrovascular pathway (white matter damage), making it a particularly potent risk factor.

Treatment

Cognitive behavioral therapy for insomnia, CBT-I, is the first-line treatment, a structured program that addresses the thoughts, behaviors, and habits that perpetuate insomnia, without medication. One year-long trial found no cognitive benefit, though it also found that the therapy never increased the deep sleep the whole theory rests on, which makes that a result about the program rather than about the idea. CBT-I remains the recommended first-line treatment for insomnia itself.

On sleep medications, the AHA Scientific Statement reports that use was associated with a 48% increase in dementia risk. Benzodiazepines such as lorazepam and temazepam, and Z-drugs such as zolpidem, should generally be avoided in older adults regardless, because of falls, confusion, and next-day impairment. Part of the dementia association likely reflects the fact that people already developing dementia are more likely to be prescribed these drugs in the first place.

A promising new class of medications, dual orexin receptor antagonists (DORAs) such as suvorexant (Belsomra) and lemborexant (Dayvigo), work by blocking the brain’s wakefulness-promoting orexin system rather than broadly sedating the brain. In a single-night mechanistic study, suvorexant was shown to acutely decrease tau phosphorylation by 10 to 15% in cerebrospinal fluid, with a transient drop in amyloid-beta that did not hold across the full night, the first demonstration that a sleep medication can favorably modify a core biological marker of Alzheimer’s disease.

REM sleep behavior disorder: not a risk factor, a warning sign

Why this one is different

The other four conditions are risk factors, but this one is not. REM sleep behavior disorder is a sign that neurodegeneration has already started. It is the earliest clinically recognizable stage of a group of diseases called the synucleinopathies.

What it looks like

During normal REM sleep, the dream stage, the body is temporarily paralyzed, a protective mechanism that prevents people from physically acting out their dreams. In RBD, this paralysis fails, and people punch, kick, shout, and thrash during vivid, often violent dreams. The condition is diagnosed most often in men over age 50, though it is likely underestimated in women. In a cohort matching 186 women with 186 men, women were diagnosed considerably younger, at 54.9 against 62.5 years, and over a median six years 9.7% of women and 16.1% of men went on to develop a neurodegenerative disorder.

RBD is diagnosed through an overnight sleep study that confirms abnormal muscle activity during REM sleep.

How often it progresses

What makes RBD significant is how often it progresses to full neurodegenerative disease. How often this happens depends strongly on where patients were recruited, and published estimates vary widely. In long-running sleep-center cohorts, 70 to 90% eventually develop Parkinson’s disease, dementia with Lewy bodies (DLB), or multiple system atrophy within 15 years. Reviews covering a wider range of cohorts give roughly 15 to 35% within 2 to 5 years, rising toward 90% over 12 to 25 years, so a figure quoted from one center should not be read as a personal prognosis. The annual conversion rate is approximately 6.3%, and one meta-analysis projected a conversion rate of 96.6% at 14 years, though that is a statistical extrapolation from studies followed for a mean of under 5 years rather than an observed figure.

Why it shows up so early

The reason comes down to anatomy, and how these diseases spread through the brain. The toxic protein responsible, alpha-synuclein, begins aggregating in the lower brainstem, which happens to be exactly where the circuits controlling REM sleep paralysis are located. As the disease slowly ascends through the brain over years to decades, it eventually reaches the substantia nigra (causing the movement problems of Parkinson’s) and the cortex (causing dementia). This means RBD can appear decades before the full disease manifests.

The timeline before diagnosis has been mapped closely. Loss of smell appears more than 20 years ahead, constipation and other autonomic problems 10 to 16 years before, subtle cognitive decline 7 to 9 years before, and accelerating motor symptoms 3 to 5 years before.

Newer tests can now detect the misfolded protein in spinal fluid with 90 to 100% sensitivity, and blood-based markers (plasma pTau181 and amyloid-beta ratio) can predict which RBD patients will specifically develop dementia with Lewy bodies.

What to do about it

Current treatments, melatonin and clonazepam, reduce the dream-enacting behaviors and prevent injury, but they do not slow or prevent the underlying neurodegeneration. This makes RBD the ideal group for testing drugs meant to slow the disease before it does irreversible damage. Several large research programs are running now.

The practical message is straightforward enough. A diagnosis of RBD should prompt neurological follow-up and biomarker testing. The prognosis is sobering, but the window is long, potentially decades, and that is exactly where a future disease-modifying treatment would do the most good.

Circadian alignment: the clock matters separately from the sleep

The body clock

The circadian system is the body’s internal 24-hour clock. It times nearly everything, from hormone release and body temperature to immune function and gene expression. The master clock resides in a tiny brain region called the suprachiasmatic nucleus (SCN), which receives light signals directly from the eyes and uses them to synchronize the body’s internal rhythms with the external day-night cycle.

The system weakens with age, as the SCN loses neurons, melatonin production drops, rhythms flatten and fragment, and peak activity shifts earlier in the day. In Alzheimer’s disease, these changes are accelerated, post-mortem studies show significant loss of critical SCN neurons, and the degree of circadian disruption correlates with the severity of cognitive decline.

The evidence connecting circadian disruption to dementia is substantial and growing. Prospective studies following people for up to 15 years show that weaker circadian rhythms (lower amplitude of the daily activity cycle) increase Alzheimer’s risk by 39% per standard deviation decrease, and more fragmented rhythms increase risk by 22% per standard deviation increase. A study from the Rotterdam cohort found that fragmented 24-hour activity rhythms preceded amyloid-beta deposition in the brain by approximately 8 years, and this effect was stronger in carriers of the APOE ε4 gene (the strongest genetic risk factor for Alzheimer’s). Because the rhythm changes came first, this points to circadian disruption being more than an early symptom of Alzheimer’s, though an observational sequence of this kind cannot by itself establish cause.

Shift work

Shift work is the most studied form of chronic circadian misalignment. UK Biobank studies followed hundreds of thousands of people for more than a decade. Shift workers showed a 30% higher dementia risk. Those who always worked nights showed a 47% higher risk of all-cause dementia, and roughly double the risk of Alzheimer’s. The picture is not uniform across studies. In the same cohort reporting the 30% increase, night shift work among shift workers was not associated with dementia, and in a meta-analysis reporting a 12% increase for night shift, shift work overall was not significant, with the association concentrated in workers over 50. Pooled across studies, the estimate is more modest, around 13% for both shift work and night shift work. A dose-response analysis found that dementia risk increases by approximately 1% for every year of shift work exposure. The reported associations appear to persist after accounting for genetic risk, though this has not been consistent across every analysis.

Sleep regularity, the consistency of sleep-wake timing from day to day, has emerged as an independent risk factor. The most irregular sleepers face 26 to 53% higher dementia risk and have measurably smaller hippocampi compared to those with regular schedules. “Social jet lag“, the mismatch between biological and social time that occurs when people keep very different schedules on workdays versus weekends, has been associated with reduced cognitive performance and decreased connectivity between brain networks important for memory.

The clock affects the brain even when sleep is normal

Circadian disruption appears to reach the brain through routes that do not run through sleep at all. Animal studies have shown that deleting the core clock gene BMAL1 causes widespread brain inflammation and synaptic degeneration even when sleep patterns remain normal. The circadian system also regulates the daily rhythm of amyloid-beta production and clearance, the timing of microglial (brain immune cell) activation, protein quality control systems, and blood-brain barrier integrity. When these rhythms are disrupted, the brain may lose some of its ability to time maintenance and repair correctly.

The relationship between circadian disruption and neurodegeneration is bidirectional, creating a vicious cycle. Circadian disruption appears to accelerate brain pathology, and brain pathology, particularly loss of SCN neurons, further weakens circadian rhythms, which may accelerate the process again. This self-reinforcing cycle may explain why sleep and circadian disturbances often appear years to decades before clinical dementia.

What helps

Bright light therapy, meaning exposure to bright light in the morning, typically 1,000 to 10,000 lux, has been shown in randomized trials to attenuate cognitive decline, improve sleep, reduce depression, and decrease agitation and behavioral disturbances in people with dementia. Melatonin supplementation, typically 3 to 12 mg before bedtime, has been studied for cognitive benefit in mild Alzheimer’s disease, but trial results are mixed. It also has antioxidant and anti-inflammatory properties beyond its effect on sleep. Maintaining regular sleep-wake schedules, getting morning sunlight exposure, eating meals at consistent times, and minimizing evening light exposure are all practical strategies for strengthening circadian alignment.

What ties all five together

Five conditions, with a few themes running through all of them.

The brain’s cleaning system depends on sleep. The glymphatic system, the brain’s waste-disposal network, is, in rodent studies, far more active during sleep than during wakefulness, with the fluid-filled space between brain cells expanding by about 60% during sleep and amyloid clearing roughly twice as fast. Each sleep disorder in this domain may impair that cleaning in a different way. This comes from animal work and has not been shown for each condition in people. Short sleep reduces the time available for cleaning, OSA causes oxygen deprivation that disrupts the channels, insomnia cuts into the deep sleep when cleaning is most active, and circadian disruption throws off its timing.

Different problems arrive at the same destination. The primary mechanisms differ completely, from oxygen deprivation in apnea to stress hormones in insomnia, protein aggregation in RBD, and clock gene disruption in circadian misalignment. They converge on the same endpoints: brain inflammation, impaired protein clearance, and buildup of the proteins found in dementia.

Vicious cycles make early intervention critical. Every sleep disorder in this domain appears to have a two-way relationship with brain degeneration, where sleep problems may accelerate brain damage and brain damage in turn worsens sleep. This creates self-reinforcing cycles that may explain why sleep disturbances often appear years to decades before clinical dementia, and why intervening early, before these cycles become entrenched, is so important.

These conditions interact and compound each other. OSA worsens insomnia, insomnia disrupts circadian rhythms, circadian disruption impairs sleep quality, and all of these reduce the deep sleep needed for brain cleaning. Addressing one problem in isolation may be insufficient, comprehensive sleep health optimization is likely needed for maximum brain protection.

RBD is the exception in this set. While the other four are modifiable risk factors where intervention may prevent or delay dementia, RBD is a sign that neurodegeneration has already begun. Its inclusion here is a reminder that sleep disorders can be both causes and consequences of brain disease, and that the clinical approach must distinguish between the two.

What to actually do

  • Aim for approximately 7 hours of sleep per night, both too little and too much are associated with increased risk
  • Keep a regular schedule, go to bed and wake up at consistent times, including weekends; regularity may matter as much as duration
  • Get tested for sleep apnea if there is snoring, daytime sleepiness, or witnessed breathing pauses, CPAP treatment may be associated with lower dementia risk, though this has not been shown in randomized trials
  • Address insomnia properly, cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia itself, though a one-year trial did not show a cognitive benefit; avoid long-term use of benzodiazepines and Z-drugs in older adults
  • Pay attention to dream-enacting behaviors, acting out dreams (punching, kicking during sleep) in someone over 50 warrants medical evaluation, as it may signal early neurodegeneration
  • Strengthen circadian alignment, get bright light exposure in the morning, maintain regular meal times, and minimize bright screens before bed. Melatonin is sometimes used for sleep timing, but the trial evidence for a cognitive benefit is inconsistent and it should be discussed with a clinician rather than assumed to lower dementia risk
  • Take new sleep problems seriously, the onset of new or worsening sleep disturbance in an older adult may be an early signal of brain changes and warrants cognitive screening

If you take one thing from the whole series, make it this. The evidence that sleep matters for the brain is real and the mechanism is well described. The evidence that fixing your sleep prevents dementia does not exist yet. Fortunately the things worth doing here are worth doing anyway, for reasons that have nothing to do with dementia.

How I make this. I choose the topic, find the research through Google Scholar, PubMed, and AI tools like OpenEvidence, and decide which findings belong in the post. AI summarizes the full papers and writes the first draft. Those summaries get audited back against the sources. I read the papers to the depth each claim needs, then check the draft against them and direct the revisions. On average five to seven hours of my own time per post. Corrections welcome.

General education, not medical advice, and not a substitute for evaluation by your own clinician. Reading this does not create a physician-patient relationship. Almost everything here comes from observational research, which shows what tends to occur together rather than what causes what, and findings that hold across a population may not apply to any one person. Do not start, stop, or change any medication or treatment based on it. Abrupt discontinuation of a benzodiazepine can be dangerous. If you think you have a sleep disorder, or you are acting out dreams, see a clinician who can take your history and examine you.

References

  1. Sleep Disorders and the Risk of Cognitive Decline or Dementia: An Updated Systematic Review and Meta-Analysis of Longitudinal Studies. Zhang J, Ou J, Lu X, et al. Journal of Neurology. 2025;272(10):689.
  2. The Relationships Between Physical Activity, Sedentary Behaviour, Sleep, and Dementia: A Systematic Review and Meta-Analysis of Cohort Studies. Oye-Somefun A, Mirzadeh P, Gao-Kang J, et al. PLoS One. 2026;21(4):e0343621.
  3. The Glymphatic Pathway in Neurological Disorders. Rasmussen MK, Mestre H, Nedergaard M. Lancet Neurology. 2018;17(11):1016-1024.
  4. AQP4-Mediated Glymphatic Clearance: Sleep, Neurodegeneration, and the Translational Gap. Santerre M, Shcherbik N, Sawaya BE. Neuroscience and Biobehavioral Reviews. 2026;188:106819.
  5. Association of the Sleep Regularity Index With Incident Dementia and Brain Volume. Yiallourou SR, Cribb L, Cavuoto MG, et al. Neurology. 2024;102(2):e208029.
  6. Sleep Regularity as an Important Component of Sleep Hygiene: A Systematic Review. Kalkanis A, Lenkens D, Steiropoulos P, Testelmans D. Sleep Medicine Reviews. 2025;84:102203.
  7. Dose-Response Associations of Device-Measured Sleep Regularity and Duration With Incident Dementia in 82,391 UK Adults. Bian W, Biswas RK, Ahmadi MN, et al. BMC Public Health. 2025;25(1):516.
  8. Screening for Obstructive Sleep Apnea in Adults. Feltner C, Wallace IF, Aymes S, et al. JAMA. 2022;328(19):1951-1971.
  9. Diagnosis and Management of Obstructive Sleep Apnea. Gottlieb DJ, Punjabi NM. JAMA. 2020;323(14):1389-1400.
  10. Sleep Apnea and the Risk of Dementia: A Systematic Review and Meta-Analysis. Guay-Gagnon M, Vat S, Forget MF, et al. Journal of Sleep Research. 2022;31(5):e13589.
  11. Sleep Disorders Increase the Risk of Dementia, Alzheimer's Disease, and Cognitive Decline: A Meta-Analysis. Ungvari Z, Fekete M, Lehoczki A, et al. GeroScience. 2025;47(3):4899-4920.
  12. Chronic Intermittent Hypoxia Enhances Pathological Tau Seeding, Propagation, and Accumulation and Exacerbates Alzheimer-Like Memory and Synaptic Plasticity Deficits and Molecular Signatures. Kazim SF, Sharma A, Saroja SR, et al. Biological Psychiatry. 2022;91(4):346-358.
  13. Chronic Intermittent Hypoxia-Induced Neural Injury: Pathophysiology, Neurodegenerative Implications, and Therapeutic Insights. Jia NN, Yao MF, Zhu CX, et al. CNS Neuroscience & Therapeutics. 2025;31(4):e70384.
  14. Association of Hypoxemia Due to Obstructive Sleep Apnea With White Matter Hyperintensities and Temporal Lobe Changes in Older Adults. Berisha DE, Rizvi B, Chappel-Farley MG, et al. Neurology. 2025;104(11):e213639.
  15. Associations of Obstructive Sleep Apnea With A/T/N Biomarkers, Neuroimaging Abnormalities, Neurodegenerative Progression, and CPAP-Related Changes in Alzheimer's Disease. Zheng W, Zhou Y, Lu M, Wang Y. Sleep Medicine. 2026;144:108975.
  16. Obstructive Sleep Apnoea Syndrome and Future Risk of Dementia Among Individuals Managed in UK General Practice. Wang J, Subramanian A, Cockburn N, et al. Thorax. 2025;80(3):167-174.
  17. Obstructive Sleep Apnea Treatment and Dementia Risk in Older Adults. Dunietz GL, Chervin RD, Burke JF, Conceicao AS, Braley TJ. Sleep. 2021;44(9):zsab076.
  18. Improvements in Cognitive Function and Quantitative Sleep Electroencephalogram in Obstructive Sleep Apnea After Six Months of Continuous Positive Airway Pressure Treatment. D'Rozario AL, Hoyos CM, Wong KKH, et al. Sleep. 2022;45(6):zsac013.
  19. Microstructural Changes in Normal-Appearing White Matter in Male Sleep Apnea Patients Are Reversible After Treatment: A Pilot Study. Salsone M, Caligiuri ME, Castronovo V, et al. Journal of Neuroscience Research. 2021;99(10):2646-2656.
  20. Insomnia Phenotypes, Cardiovascular Risk and Their Link to Brain Health. Fernandez-Mendoza J. Circulation Research. 2025;137(5):727-745.
  21. Associations of Chronic Insomnia, Longitudinal Cognitive Outcomes, Amyloid-PET, and White Matter Changes in Cognitively Normal Older Adults. Carvalho DZ, Kolla BP, McCarter SJ, et al. Neurology. 2025;105(7):e214155.
  22. Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association. Gottesman RF, Lutsey PL, Benveniste H, et al. Stroke. 2024;55(3):e61.
  23. Chronic Insomnia Is Associated With Nyctohemeral Activation of the Hypothalamic-Pituitary-Adrenal Axis: Clinical Implications. Vgontzas AN, Bixler EO, Lin HM, et al. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3787.
  24. What Is the Role of Glucocorticoids in the Effects of Stress on the Brain? Benarroch E. Neurology. 2025;105(2):e213874.
  25. Chronic Stress, Cortisol Dysregulation, and Neurodegenerative Vulnerability: Mechanistic Pathways Linking HPA-Axis Dysfunction to Alzheimer's Disease Risk. Almalki DF, Alkabkabi RA, Wayyani RA, et al. Frontiers in Aging Neuroscience. 2026;18:1883880.
  26. The Impact of Cognitive Behavioral Therapy for Insomnia on Cognitive Performance and Amyloid Beta in Older Adults: A Randomized Controlled Trial. Siengsukon CF, Hand LK, Nelson E, et al. Alzheimer's & Dementia. 2026;22(6):e71591.
  27. Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression. da Silva AMP, Tudella GCN, Gonçalves OR, et al. Drugs. 2026;86(7):1103-1119.
  28. American Geriatrics Society Identifies Five Things That Healthcare Providers and Patients Should Question. Journal of the American Geriatrics Society. 2013;61(4):622-631.
  29. Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. Lucey BP, Liu H, Toedebusch CD, et al. Annals of Neurology. 2023;94(1):27.
  30. Sleep and Sleep Disorders in People With Parkinson's Disease. Iranzo A, Cochen De Cock V, Fantini ML, Pérez-Carbonell L, Trotti LM. Lancet Neurology. 2024;23(9):925-937.
  31. Risk Factors for Possible REM Sleep Behavior Disorder: A CLSA Population-Based Cohort Study. Yao C, Fereshtehnejad SM, Keezer MR, et al. Neurology. 2019;92(5):e475-e485.
  32. Importance of Rapid Eye Movement Sleep Behavior Disorder to the Primary Care Physician. McCarter SJ, Howell MJ. Mayo Clinic Proceedings. 2016;91(10):1460-1466.
  33. Brain Metabolism Related to Mild Cognitive Impairment and Phenoconversion in Patients With Isolated REM Sleep Behavior Disorder. Yoon EJ, Lee JY, Kim H, et al. Neurology. 2022;98(24):e2413-e2424.
  34. Risk and Predictors of Dementia and Parkinsonism in Idiopathic REM Sleep Behaviour Disorder: A Multicentre Study. Postuma RB, Iranzo A, Hu M, et al. Brain. 2019;142(3):744-759.
  35. From Mechanisms to Future Therapy: A Synopsis of Isolated REM Sleep Behavior Disorder as Early Synuclein-Related Disease. Stefani A, Antelmi E, Arnaldi D, et al. Molecular Neurodegeneration. 2025;20(1).
  36. Evolution of Motor and Nonmotor Characteristics in an Idiopathic/Isolated REM Sleep Behavior Disorder Cohort. Delva A, Fereshtehnejad SM, Vo A, et al. Neurology. 2025;105(7):e214108.
  37. Evolution of Prodromal Parkinson's Disease and Dementia With Lewy Bodies: A Prospective Study. Fereshtehnejad SM, Yao C, Pelletier A, et al. Brain. 2019;142(7):2051-2067.
  38. Detection of α-Synuclein in CSF by RT-QuIC in Patients With Isolated Rapid-Eye-Movement Sleep Behaviour Disorder: A Longitudinal Observational Study. Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Lancet Neurology. 2021;20(3):203-212.
  39. Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues. Kong W, Satoh K, Shimamura MI, et al. Journal of Neurochemistry. 2026;170(5):e70435.
  40. Plasma pTau181 and Amyloid Markers Predict Conversion to Dementia in Idiopathic REM Sleep Behaviour Disorder. Delva A, Pelletier A, Somerville E, et al. Brain. 2025;148(6):2049-2059.
  41. Idiopathic Rapid Eye Movement Sleep Behaviour Disorder: Diagnosis, Management, and the Need for Neuroprotective Interventions. Iranzo A, Santamaria J, Tolosa E. Lancet Neurology. 2016;15(4):405.
  42. Biomarkers of Conversion to α-Synucleinopathy in Isolated Rapid-Eye-Movement Sleep Behaviour Disorder. Miglis MG, Adler CH, Antelmi E, et al. Lancet Neurology. 2021;20(8):671-684.
  43. Association Between Circadian Rhythms and Neurodegenerative Diseases. Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Lancet Neurology. 2019;18(3):307-318.
  44. Importance of Bmal1 in Alzheimer's Disease and Associated Aging-Related Diseases: Mechanisms and Interventions. Fan R, Peng X, Xie L, et al. Aging Cell. 2022;21(10):e13704.
  45. Circadian Disturbances in Alzheimer's Disease Progression: A Prospective Observational Cohort Study of Community-Based Older Adults. Li P, Gao L, Gaba A, et al. Lancet Healthy Longevity. 2020;1(3):e96-e105.
  46. Sleep, 24-Hour Activity Rhythms, and Subsequent Amyloid-β Pathology. Nguyen Ho PT, Hoepel SJW, Rodriguez-Ayllon M, et al. JAMA Neurology. 2024;81(8):824-834.
  47. Association of Shift Work With Incident Dementia: A Community-Based Cohort Study. Liao H, Pan D, Deng Z, et al. BMC Medicine. 2022;20(1):484.
  48. The Association of Night Shift Work With the Risk of All-Cause Dementia and Alzheimer's Disease: A Longitudinal Study of 245,570 UK Biobank Participants. Ling Y, Yuan S, Huang X, et al. Journal of Neurology. 2023;270(7):3499-3510.
  49. Impact of Shift Work on Dementia: A Systematic Review and Dose-Response Meta-Analysis. Gao Y, Fu X, Hu H, et al. Public Health. 2023;223:80.
  50. Sleep Timing, Chronotype and Social Jetlag: Impact on Cognitive Abilities and Psychiatric Disorders. Taillard J, Sagaspe P, Philip P, Bioulac S. Biochemical Pharmacology. 2021;191:114438.
  51. Sleep Misalignment and Cognitive Decline in Everyday Life: Social Jet Lag as a Proxy for Chronic Sleep Deprivation. Sato TG, Takahashi M, Nishida M. Journal of Sleep Research. 2026;35(3):e70223.
  52. Circadian Rhythms and the Light-Dark Cycle Interact to Regulate Amyloid-Beta Plaque Accumulation and Tau Phosphorylation in 5xFAD Mice. King MW, Jacob SM, Sharma A, Lawrence JH, Musiek ES. Alzheimer's & Dementia. 2025;21(11):e70885.
  53. The Effects of Light Therapy on Sleep, Depression, Neuropsychiatric Behaviors, and Cognition Among People Living With Dementia: A Meta-Analysis of Randomized Controlled Trials. Aini N, Chen R, Chu H, et al. American Journal of Geriatric Psychiatry. 2024;32(6):681-706.
  54. Bright Light Therapy and Circadian Cycles in Institutionalized Elders. Rubiño JA, Gamundí A, Akaarir M, et al. Frontiers in Neuroscience. 2020;14:359.
  55. Melatonin for Sleep and Cognitive Outcomes in Older Adults With Cognitive Impairment: A Meta-Analysis of Randomised Controlled Trials. Mdluli NT, Banda KJ, Chang YC. Age and Ageing. 2025;54(11).
  56. Neurocognitive Effects of Melatonin Treatment in Healthy Adults and Individuals With Alzheimer's Disease and Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sumsuzzman DM, Choi J, Jin Y, Hong Y. Neuroscience and Biobehavioral Reviews. 2021;127:459-473.
  57. The Effects of Sleep Duration on the Risk of Dementia Incidence in Short and Long Follow-Up Studies: A Systematic Review and Meta-Analysis. Howard C, Mukadam N, Hui EK, Livingston G. Sleep Medicine. 2025;125:126-135.
  58. REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. St Louis EK, Boeve BF. Mayo Clinic Proceedings. 2017;92(11):1723-1736.
  59. Phenoconversion in Women and Men With Isolated REM Sleep Behavior Disorder. Schumacher-Schuh CH, Bunting-Perry L, Videnovic A, et al. Neurology. 2024;103(10):e209993.
  60. Association of Sleep Duration in Middle and Old Age With Incidence of Dementia. Sabia S, Fayosse A, Dumurgier J, et al. Nature Communications. 2021;12(1):2289.

Read more